{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T01:39:29Z","timestamp":1773106769079,"version":"3.50.1"},"reference-count":160,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Metabolites"],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD), the most widespread chronic liver disease worldwide, confers a significant burden on health systems and leads to increased mortality and morbidity through several extrahepatic complications. NAFLD comprises a broad spectrum of liver-related disorders, including steatosis, cirrhosis, and hepatocellular carcinoma. It affects almost 30% of adults in the general population and up to 70% of people with type 2 diabetes (T2DM), sharing common pathogenetic pathways with the latter. In addition, NAFLD is closely related to obesity, which acts in synergy with other predisposing conditions, including alcohol consumption, provoking progressive and insidious liver damage. Among the most potent risk factors for accelerating the progression of NAFLD to fibrosis or cirrhosis, diabetes stands out. Despite the rapid rise in NAFLD rates, identifying the optimal treatment remains a challenge. Interestingly, NAFLD amelioration or remission appears to be associated with a lower risk of T2DM, indicating that liver-centric therapies could reduce the risk of developing T2DM and vice versa. Consequently, assessing NAFLD requires a multidisciplinary approach to identify and manage this multisystemic clinical entity early. With the continuously emerging new evidence, innovative therapeutic strategies are being developed for the treatment of NAFLD, prioritizing a combination of lifestyle changes and glucose-lowering medications. Based on recent evidence, this review scrutinizes all practical and sustainable interventions to achieve a resolution of NAFLD through a multimodal approach.<\/jats:p>","DOI":"10.3390\/metabo13040517","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T04:09:50Z","timestamp":1680581390000},"page":"517","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Therapeutic Potentials of Reducing Liver Fat in Non-Alcoholic Fatty Liver Disease: Close Association with Type 2 Diabetes"],"prefix":"10.3390","volume":"13","author":[{"given":"Georgios","family":"Tsamos","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Norfolk and Norwich University Hospital, Norwich NR4 7UY, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0481-344X","authenticated-orcid":false,"given":"Dimitra","family":"Vasdeki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, 54636 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5853-1352","authenticated-orcid":false,"given":"Theocharis","family":"Koufakis","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, 54636 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7097-2927","authenticated-orcid":false,"given":"Vassiliki","family":"Michou","sequence":"additional","affiliation":[{"name":"Sports Medicine Laboratory, School of Physical Education & Sport Science, Aristotle University of Thessaloniki, 57001 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2718-7480","authenticated-orcid":false,"given":"Kali","family":"Makedou","sequence":"additional","affiliation":[{"name":"Laboratory of Biological Chemistry, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, 54636 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georgios","family":"Tzimagiorgis","sequence":"additional","affiliation":[{"name":"Laboratory of Biological Chemistry, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, 54636 Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: A systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"15539","DOI":"10.3748\/wjg.v20.i42.15539","article-title":"Histopathology of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"20","author":"Takahashi","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_4","unstructured":"GBD 2016 Disease and Injury Incidence and Prevalence Collaborators (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390, 1211\u20131259."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(17)32366-8","article-title":"Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016","volume":"390","author":"Gakidou","year":"2017","journal-title":"Lancet"},{"key":"ref_6","unstructured":"International Diabetes Federation (2021, September 12). IDF Diabetes Atlas Tenth Edition. Available online: https:\/\/diabetesatlas.org\/."},{"key":"ref_7","unstructured":"(2020, March 01). 9th Edition|IDF Diabetes Atlas. Available online: https:\/\/diabetesatlas.org\/atlas\/ninth-edition\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1055\/s-0034-1366278","article-title":"Definition, Classification and Diagnosis of Diabetes Mellitus","volume":"122","author":"Kerner","year":"2014","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jgh.13264","article-title":"Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis","volume":"31","author":"Ballestri","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1002\/hep.26183","article-title":"Clinical availability of nonalcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in korean men: 5-year prospective cohort study","volume":"57","author":"Park","year":"2012","journal-title":"Hepatology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.dld.2017.12.018","article-title":"Nonalcoholic fatty liver disease as a sentinel marker for the development of diabetes mellitus in non-obese subjects","volume":"50","author":"Kim","year":"2018","journal-title":"Dig. Liver Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in Adipose Tissue and Hepatic Lipid Kinetics in Obese Men and Women With Nonalcoholic Fatty Liver Disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1053\/j.gastro.2008.01.075","article-title":"Liver, Muscle, and Adipose Tissue Insulin Action Is Directly Related to Intrahepatic Triglyceride Content in Obese Subjects","volume":"134","author":"Korenblat","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.cmet.2017.08.002","article-title":"Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases","volume":"27","author":"Samuel","year":"2018","journal-title":"Cell Metab."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1055\/s-2001-12927","article-title":"Etiopathogenesis of Nonalcoholic Steatohepatitis","volume":"21","author":"Chitturi","year":"2001","journal-title":"Semin. Liver Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0168-8278(97)80496-5","article-title":"Impaired mitochondrial function in microvesicular steatosis effects of drugs, ethanol, hormones and cytokines","volume":"26","author":"Fromenty","year":"1997","journal-title":"J. Hepatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cld.2007.02.011","article-title":"Pathogenesis of Non-alcoholic Steatohepatitis: Human Data","volume":"11","author":"Edmison","year":"2007","journal-title":"Clin. Liver Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S377","DOI":"10.1046\/j.1440-1746.17.s3.31.x","article-title":"Non-alcoholic steatohepatitis: Definitions and pathogenesis","volume":"17","author":"Day","year":"2002","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1152\/physrev.00063.2017","article-title":"Mechanisms of Insulin Action and Insulin Resistance","volume":"98","author":"Petersen","year":"2018","journal-title":"Physiol. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jhep.2020.01.013","article-title":"NAFLD as a driver of chronic kidney disease","volume":"72","author":"Byrne","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2337\/dci19-0064","article-title":"Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes","volume":"43","author":"Cusi","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3637","DOI":"10.1210\/jc.2013-1519","article-title":"Resolution of Fatty Liver and Risk of Incident Diabetes","volume":"98","author":"Sung","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1042\/CS20070402","article-title":"Non-alcoholic fatty liver disease: An overview of prevalence, diagnosis, pathogenesis and treatment considerations","volume":"115","author":"Preiss","year":"2008","journal-title":"Clin. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1080\/11026480410033539","article-title":"WHO\u2019s global strategy on diet, physical activity and health: Response to a worldwide epidemic of non-communicable diseases","volume":"48","author":"Waxman","year":"2004","journal-title":"Scand. J. Nutr.\/Naringsforsk."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2337\/dc06-2032","article-title":"Habitual Physical Activity Is Associated With Intrahepatic Fat Content in Humans","volume":"30","author":"Perseghin","year":"2007","journal-title":"Diabetes Care"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/hep.22940","article-title":"Independent effects of physical activity in patients with nonalcoholic fatty liver disease","volume":"50","author":"George","year":"2009","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"srep43029","DOI":"10.1038\/srep43029","article-title":"High-Intensity Aerobic Exercise Improves Both Hepatic Fat Content and Stiffness in Sedentary Obese Men with Nonalcoholic Fatty Liver Disease","volume":"7","author":"Oh","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/dom.12809","article-title":"Long-term effect of exercise on improving fatty liver and cardiovascular risk factors in obese adults: A 1-year follow-up study","volume":"19","author":"Zhang","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20120684","article-title":"Resistance exercise improves autonomic regulation at rest and haemodynamic response to exercise in non-alcoholic fatty liver disease","volume":"125","author":"Jakovljevic","year":"2013","journal-title":"Clin. Sci."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Pennisi, G., Celsa, C., Spatola, F., Dallio, M., Federico, A., and Petta, S. (2019). Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. Int. J. Environ. Public Health, 16.","DOI":"10.3390\/ijerph16224334"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6318","DOI":"10.3748\/wjg.v22.i27.6318","article-title":"Effectiveness of exercise in hepatic fat mobilization in non-alcoholic fatty liver disease: Systematic review","volume":"22","author":"Golabi","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0140-6736(12)61031-9","article-title":"Effect of physical inactivity on major non-communicable diseases worldwide: An analysis of burden of disease and life expectancy","volume":"380","author":"Lee","year":"2012","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2010.1505","article-title":"Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: A randomized trial","volume":"304","author":"Goodpaster","year":"2010","journal-title":"JAMA"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s00125-009-1641-z","article-title":"The effects of aerobic exercise on metabolic risk, insulin sensitivity and intrahepatic lipid in healthy older people from the Hertfordshire Cohort Study: A randomised controlled trial","volume":"53","author":"Finucane","year":"2010","journal-title":"Diabetologia"},{"key":"ref_39","first-page":"E1033","article-title":"Effects of aerobic vs. resistance training on visceral and liver fat stores, liver enzymes, and insulin resistance by HOMA in overweight adults from STRRIDE AT\/RT","volume":"301","author":"Slentz","year":"2011","journal-title":"Am. J. Physiol. Metab."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jhep.2013.04.013","article-title":"Community-based lifestyle modification programme for non-alcoholic fatty liver disease: A randomized controlled trial","volume":"59","author":"Wong","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.3748\/wjg.v20.i15.4382","article-title":"Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial","volume":"20","author":"Buch","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.diabres.2015.05.033","article-title":"Volume-dependent effect of supervised exercise training on fatty liver and visceral adiposity index in subjects with type 2 diabetes The Italian Diabetes Exercise Study (IDES)","volume":"109","author":"Balducci","year":"2015","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/CS20150447","article-title":"Dissociation between exercise-induced reduction in liver fat and changes in hepatic and peripheral glucose homoeostasis in obese patients with non-alcoholic fatty liver disease","volume":"130","author":"Cuthbertson","year":"2015","journal-title":"Clin. Sci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.biopha.2016.02.017","article-title":"Effects of endurance and endurance\u2013strength exercise on biochemical parameters of liver function in women with abdominal obesity","volume":"80","author":"Skrypnik","year":"2016","journal-title":"Biomed. Pharmacother."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1080\/02772248.2018.1430233","article-title":"Effects of aerobic exercise on histopathology and toxicology of ZnO and nano ZnO in male rats","volume":"100","author":"Farzanegi","year":"2018","journal-title":"Toxicol. Environ. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"m4747","DOI":"10.1136\/bmj.m4747","article-title":"Management of non-alcoholic fatty liver disease","volume":"372","author":"Petroni","year":"2021","journal-title":"BMJ"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Trenell","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"i4428","DOI":"10.1136\/bmj.i4428","article-title":"Non-alcoholic fatty liver disease (NAFLD): Summary of NICE guidance","volume":"354","author":"Glen","year":"2016","journal-title":"BMJ"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.tem.2009.11.005","article-title":"Metabolic reprogramming, caloric restriction and aging","volume":"21","author":"Anderson","year":"2010","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1001\/jamainternmed.2018.2933","article-title":"The Carbohydrate-Insulin Model of Obesity: Beyond \u201cCalories In, Calories Out\u201d","volume":"178","author":"Ludwig","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"100256","DOI":"10.1016\/j.jhepr.2021.100256","article-title":"Treatment of NAFLD with intermittent calorie restriction or low-carb high-fat diet\u2014A randomised controlled trial","volume":"3","author":"Holmer","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis","volume":"149","author":"Friedman","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1053\/j.gastro.2009.01.048","article-title":"Dietary Fat and Carbohydrates Differentially Alter Insulin Sensitivity During Caloric Restriction","volume":"136","author":"Kirk","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Petracca, G., Csermely, A., Beatrice, G., and Targher, G. (2020). Sodium-Glucose Cotransporter-2 Inhibitors for Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials. Metabolites, 11.","DOI":"10.3390\/metabo11010022"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1053\/jhep.2003.50132","article-title":"Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis","volume":"37","author":"Musso","year":"2003","journal-title":"Hepatology"},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Perdomo, C.M., Fr\u00fchbeck, G., and Escalada, J. (2019). Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. Nutrients, 11.","DOI":"10.3390\/nu11030677"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1002\/hep.23535","article-title":"Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease","volume":"51","author":"Abdelmalek","year":"2010","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"10621","DOI":"10.3748\/wjg.v21.i37.10621","article-title":"Oily fish, coffee and walnuts: Dietary treatment for nonalcoholic fatty liver disease","volume":"21","author":"Gupta","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1024\/0300-9831\/a000246","article-title":"Antidiabetic and Antioxidant Effects of Apple Cider Vinegar on Normal and Streptozotocin-Induced Diabetic Rats","volume":"88","author":"Halima","year":"2018","journal-title":"Int. J. Vitam. Nutr. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1079\/BJN20061740","article-title":"Dietary acetic acid reduces serum cholesterol and triacylglycerols in rats fed a cholesterol-rich diet","volume":"95","author":"Fushimi","year":"2006","journal-title":"Br. J. Nutr."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.3923\/pjbs.2008.2634.2638","article-title":"Apple Cider Vinegar Attenuates Lipid Profile in Normal and Diabetic Rats","volume":"11","author":"Shishehbor","year":"2008","journal-title":"Pak. J. Biol. Sci."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1186\/s12906-021-03351-w","article-title":"The effect of apple cider vinegar on lipid profiles and glycemic parameters: A systematic review and meta-analysis of randomized clinical trials","volume":"21","author":"Hadi","year":"2021","journal-title":"BMC Complement. Med. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"9284987","DOI":"10.1155\/2020\/9284987","article-title":"Beneficial Effects of Apple Vinegar on Hyperglycemia and Hyperlipidemia in Hypercaloric-Fed Rats","volume":"2020","author":"Ousaaid","year":"2020","journal-title":"J. Diabetes Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/hep.24242","article-title":"Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects","volume":"53","author":"Haufe","year":"2011","journal-title":"Hepatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3945\/ajcn.110.007674","article-title":"Short-term weight loss and hepatic triglyceride reduction: Evidence of a metabolic advantage with dietary carbohydrate restriction","volume":"93","author":"Browning","year":"2011","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s12603-016-0809-8","article-title":"Effect of a low glycemic index Mediterranean diet on non-alcoholic fatty liver disease. A randomized controlled clinici trial","volume":"21","author":"Misciagna","year":"2017","journal-title":"J. Nutr. Health Aging"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Greco, M., Milic, N., Accattato, F., Foti, D., Gulletta, E., and Luzza, F. (2017). Effect of Mediterranean Diet and Antioxidant Formulation in Non-Alcoholic Fatty Liver Disease: A Randomized Study. Nutrients, 9.","DOI":"10.3390\/nu9080870"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/j.gastro.2016.10.007","article-title":"Isocaloric Diets High in Animal or Plant Protein Reduce Liver Fat and Inflammation in Individuals With Type 2 Diabetes","volume":"152","author":"Markova","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1017\/S000711451800137X","article-title":"Improvements in clinical characteristics of patients with non-alcoholic fatty liver disease, after an intervention based on the Mediterranean lifestyle: A randomised controlled clinical trial","volume":"120","author":"Katsagoni","year":"2018","journal-title":"Br. J. Nutr."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Marin-Alejandre, B.A., Abete, I., Cantero, I., Monreal, J.I., Elorz, M., Herrero, J.I., Benito-Boillos, A., Quiroga, J., Martinez-Echeverria, A., and Uriz-Otano, J.I. (2019). The Metabolic and Hepatic Impact of Two Personalized Dietary Strategies in Subjects with Obesity and Nonalcoholic Fatty Liver Disease: The Fatty Liver in Obesity (FLiO) Randomized Controlled Trial. Nutrients, 11.","DOI":"10.3390\/nu11102543"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","article-title":"Effect of green-Mediterranean diet on intrahepatic fat: The DIRECT PLUS randomised controlled trial","volume":"70","author":"Meir","year":"2021","journal-title":"Gut"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1111\/liv.14596","article-title":"High-protein diet more effectively reduces hepatic fat than low-protein diet despite lower autophagy and FGF21 levels","volume":"40","author":"Xu","year":"2020","journal-title":"Liver Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e12630","DOI":"10.1111\/ijpo.12630","article-title":"Effects of a carbohydrate-restricted diet on hepatic lipid content in adolescents with non-alcoholic fatty liver disease: A pilot, randomized trial","volume":"15","author":"Goss","year":"2020","journal-title":"Pediatr. Obes."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt","year":"2015","journal-title":"Nat. Rev. Dis. Prim."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3389\/fmed.2020.00361","article-title":"Advances in the Involvement of Gut Microbiota in Pathophysiology of NAFLD","volume":"7","author":"Jiang","year":"2020","journal-title":"Front. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1007\/BF03349226","article-title":"Critical assessment of the current guidelines for the management and treatment of morbidly obese patients","volume":"30","author":"Burguera","year":"2007","journal-title":"J. Endocrinol. Investig."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrgastro.2016.170","article-title":"Bariatric surgery for obesity and metabolic disorders: State of the art","volume":"14","author":"Nguyen","year":"2016","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"953804","DOI":"10.3389\/fsurg.2022.953804","article-title":"Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy effects on obesity comorbidities: A systematic review and meta-analysis","volume":"9","author":"Alghamdi","year":"2022","journal-title":"Front. Surg."},{"key":"ref_82","unstructured":"Seeras, K., and Lopez, P.P. (2021). Sleeve Gastrectomy, Starpearls Pubilshing."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.cgh.2018.10.017","article-title":"Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis","volume":"17","author":"Lee","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.soard.2018.06.007","article-title":"In nonalcoholic fatty liver disease, Roux-en-Y gastric bypass improves liver histology while persistent disease is associated with lower improvements in waist circumference and glycemic control","volume":"14","author":"Schwenger","year":"2018","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000282102","article-title":"Surgical Treatment of Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease","volume":"28","author":"Weiner","year":"2010","journal-title":"Dig. Dis."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s11695-011-0559-y","article-title":"Effect of Bariatric Surgery on Liver Fibrosis","volume":"22","author":"Moretto","year":"2011","journal-title":"Obes. Surg."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s11695-011-0579-7","article-title":"Improvement of Nonalcoholic Fatty Liver Disease After Bariatric Surgery in Morbidly Obese Chinese Patients","volume":"22","author":"Tai","year":"2011","journal-title":"Obes. Surg."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"382","DOI":"10.4254\/wjh.v4.i12.382","article-title":"Surgically induced weight loss by gastric bypass improves non alcoholic fatty liver disease in morbid obese patients","volume":"4","author":"Vargas","year":"2012","journal-title":"World J. Hepatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s11605-014-2678-y","article-title":"Bariatric surgery improves histological features of nonalcoholic fatty liver disease and liver fibrosis","volume":"19","author":"Taitano","year":"2015","journal-title":"J. Gastrointest. Surg."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1053\/j.gastro.2015.04.014","article-title":"Bariatric Surgery Reduces Features of Nonalcoholic Steatohepatitis in Morbidly Obese Patients","volume":"149","author":"Lassailly","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1007\/s00464-016-5082-8","article-title":"The effects of bariatric surgeries on nonalcoholic fatty liver disease","volume":"31","author":"Aldoheyan","year":"2017","journal-title":"Surg. Endosc."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40608-017-0168-y","article-title":"Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery","volume":"4","author":"Parker","year":"2017","journal-title":"BMC Obes."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1007\/s11695-018-3466-7","article-title":"Laparoscopic Sleeve Gastrectomy Resolves NAFLD: Another Formal Indication for Bariatric Surgery?","volume":"28","author":"Esquivel","year":"2018","journal-title":"Obes. Surg."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1148\/radiol.2018181134","article-title":"Monitoring Fatty Liver Disease with MRI Following Bariatric Surgery: A Prospective, Dual-Center Study","volume":"290","author":"Pooler","year":"2019","journal-title":"Radiology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.diabet.2019.12.007","article-title":"Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials","volume":"46","author":"Mantovani","year":"2020","journal-title":"Diabetes Metab."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1530\/JOE-19-0007","article-title":"Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis","volume":"241","author":"Kalavalapalli","year":"2019","journal-title":"J. Endocrinol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.metabol.2019.07.009","article-title":"Effects of sodium-glucose co-transporter-2 (SGLT2) inhibitors on non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis: Ex quo et quo vadimus?","volume":"98","author":"Katsiki","year":"2019","journal-title":"Metabolism"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2337\/diabetes.51.3.797","article-title":"The Effects of Rosiglitazone on Insulin Sensitivity, Lipolysis, and Hepatic and Skeletal Muscle Triglyceride Content in Patients With Type 2 Diabetes","volume":"51","author":"Mayerson","year":"2002","journal-title":"Diabetes"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e3413","DOI":"10.1002\/dmrr.3413","article-title":"Effects of sodium-glucose co-transporter 2 inhibitors on liver parameters and steatosis: A meta-analysis of randomized clinical trials","volume":"37","author":"Neves","year":"2021","journal-title":"Diabetes Metab. Res. Rev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/dom.13061","article-title":"Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study","volume":"20","author":"Shibuya","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00125-018-4675-2","article-title":"Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: A double-blind randomised placebo-controlled study","volume":"61","author":"Eriksson","year":"2018","journal-title":"Diabetologia"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1007\/s00125-018-4702-3","article-title":"Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: Results from randomised trials including the EMPA-REG OUTCOME\u00ae trial","volume":"61","author":"Sattar","year":"2018","journal-title":"Diabetologia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/nrendo.2016.135","article-title":"PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD","volume":"13","author":"Gross","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: Pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S2213-8587(20)30303-X","article-title":"2-year remission of type 2 diabetes and pancreas morphology: A post-hoc analysis of the DiRECT open-label, cluster-randomised trial","volume":"8","author":"Hollingsworth","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1210\/clinem\/dgaa863","article-title":"Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes","volume":"106","author":"Thomas","year":"2020","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/dom.12680","article-title":"Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: A prospective randomized clinical trial using magnetic resonance imaging and spectroscopy","volume":"18","author":"Dutour","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/apt.12149","article-title":"Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: Individual patient data meta-analysis of the LEAD program","volume":"37","author":"Armstrong","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jhep.2015.08.038","article-title":"Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis","volume":"64","author":"Armstrong","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/apt.15316","article-title":"Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity","volume":"50","author":"Newsome","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: A randomized controlled trial","volume":"65","author":"Cui","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3748\/wjg.v23.i1.141","article-title":"Sitagliptin in patients with non-alcoholic steatohepatitis: A randomized, placebo-controlled trial","volume":"23","author":"Joy","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/hep.1840380427","article-title":"Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-\u03b3 ligand rosiglitazone","volume":"38","author":"Brunt","year":"2003","journal-title":"Hepatology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2008.03.078","article-title":"Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial","volume":"135","author":"Ratziu","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"305","DOI":"10.7326\/M15-1774","article-title":"Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial","volume":"165","author":"Cusi","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/dom.13584","article-title":"Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes","volume":"21","author":"Cusi","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"931","DOI":"10.2337\/dc18-1569","article-title":"The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients","volume":"42","author":"Honka","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/dom.13520","article-title":"Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"21","author":"Shimizu","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial","volume":"43","author":"Kahl","year":"2019","journal-title":"Diabetes Care"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"157","author":"Saeedi","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/ggi.14277","article-title":"Effects of different definitions of low muscle mass on its association with metabolic syndrome in older adults: A Korean nationwide study","volume":"21","author":"Jeon","year":"2021","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jhep.2018.07.019","article-title":"Statins: Old drugs as new therapy for liver diseases?","volume":"70","author":"Pose","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jhep.2015.05.006","article-title":"Statin use and non-alcoholic steatohepatitis in at risk individuals","volume":"63","author":"Dongiovanni","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of Statin Use on the Development and Progression of Nonalcoholic Fatty Liver Disease: A Nationwide Nested Case-Control Study","volume":"116","author":"Lee","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/hepr.12887","article-title":"Ezetimibe for the treatment of non-alcoholic fatty liver disease: A meta-analysis","volume":"47","author":"Nakade","year":"2017","journal-title":"Hepatol. Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"154299","DOI":"10.1016\/j.metabol.2020.154299","article-title":"Metabolic liver disease in diabetes\u2014From mechanisms to clinical trials","volume":"111","author":"Dewidar","year":"2020","journal-title":"Metabolism"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Lee, C.-H., Fu, Y., Yang, S.-J., and Chi, C.-C. (2020). Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis. Nutrients, 12.","DOI":"10.3390\/nu12092769"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Valenzuela, R., and Videla, L.A. (2020). Impact of the Co-Administration of N-3 Fatty Acids and Olive Oil Components in Preclinical Nonalcoholic Fatty Liver Disease Models: A Mechanistic View. Nutrients, 12.","DOI":"10.3390\/nu12020499"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41467-023-35944-z","article-title":"Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice","volume":"14","author":"Huang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1001\/jamainternmed.2021.5714","article-title":"Association of Statin Therapy Initiation With Diabetes Progression: A Retrospective Matched-Cohort Study","volume":"181","author":"Mansi","year":"2021","journal-title":"JAMA Intern. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/dom.14322","article-title":"Nonalcoholic fatty liver disease as a metabolic disease in humans: A literature review","volume":"23","author":"Cariou","year":"2021","journal-title":"Diabetes Obes. Metab."},{"key":"ref_137","first-page":"116","article-title":"Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet","volume":"328","author":"Kong","year":"2008","journal-title":"Experiment"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.cmet.2007.10.014","article-title":"Hepatic stearoyl-CoA desaturase-1 deficiency protects mice from carbohydrate-induced adiposity and hepatic steatosis","volume":"6","author":"Miyazaki","year":"2007","journal-title":"Cell Metab."},{"key":"ref_142","unstructured":"(2018, November 01). One-Year Results of the Global Phase 2b Randomized Placebo-Controlled ARREST Trial of Aramchol, a Stearoyl CoA Desaturasemodulator in NASH Patients. Available online: https:\/\/www.natap.org\/2018\/AASLD\/AASLD_222.htm."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American association of clinical endocrinologists and american college of endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr. Pract."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2337\/db08-1074","article-title":"Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver","volume":"58","author":"Kotronen","year":"2009","journal-title":"Diabetes"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1172\/JCI26991","article-title":"Critical role of stearoyl-CoA desaturase-1 (SCD1) in the onset of diet-induced hepatic insulin resistance","volume":"116","author":"Pocai","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","article-title":"Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis","volume":"315","author":"Khera","year":"2016","journal-title":"JAMA"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2337\/diacare.27.5.1077","article-title":"Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients","volume":"27","author":"Damci","year":"2004","journal-title":"Diabetes Care"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/sj.ijo.0802925","article-title":"Orlistat in responding obese type 2 diabetic patients: Meta-analysis findings and cost-effectiveness as rationales for reimbursement in Sweden and Switzerland","volume":"29","author":"Ruof","year":"2005","journal-title":"Int. J. Obes."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3389\/fendo.2020.00070","article-title":"Effect of Weight Loss Medications on Hepatic Steatosis and Steatohepatitis: A Systematic Review","volume":"11","author":"Pan","year":"2020","journal-title":"Front. Endocrinol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"170939","DOI":"10.1016\/j.peptides.2023.170939","article-title":"An update on peptide-based therapies for type 2 diabetes and obesity","volume":"161","author":"Bailey","year":"2023","journal-title":"Peptides"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S2213-8587(22)00070-5","article-title":"Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial","volume":"10","author":"Gastaldelli","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Cuthbertson, D.J., Irwin, A., Gardner, C.J., Daousi, C., Purewal, T., Furlong, N., Goenka, N., Thomas, E.L., Adams, V.L., and Pushpakom, S.P. (2012). Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050117"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S2213-8587(21)00179-0","article-title":"Effects of liraglutide on visceral and ectopic fat in adults with overweight and obesity at high cardiovascular risk: A randomised, double-blind, placebo-controlled, clinical trial","volume":"9","author":"Neeland","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Mantovani, A., Petracca, G., Beatrice, G., Csermely, A., Lonardo, A., and Targher, G. (2021). Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials. Metabolites, 11.","DOI":"10.3390\/metabo11020073"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., and Sabb\u00e0, C. (2022). Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients, 14.","DOI":"10.3390\/nu14214673"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/apt.16608","article-title":"Randomised clinical trial: Semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging","volume":"54","author":"Flint","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: A systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_160","first-page":"158","article-title":"Nonalcoholic Fatty Liver Disease Screening in Type 2 Diabetes Mellitus Patients in the Primary Care Setting","volume":"5","author":"Lai","year":"2020","journal-title":"Hepatol. Commun."}],"container-title":["Metabolites"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-1989\/13\/4\/517\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:09:38Z","timestamp":1760123378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-1989\/13\/4\/517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,4]]},"references-count":160,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["metabo13040517"],"URL":"https:\/\/doi.org\/10.3390\/metabo13040517","relation":{},"ISSN":["2218-1989"],"issn-type":[{"value":"2218-1989","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,4]]}}}